What is BMY's current stock price?

As of now, BMY is trading at $52.41, with a daily change of +2.36%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BMY Stock Analysis & IQ Rating | Bristol-Myers Squibb

BMY

Bristol-Myers Squibb

$52.41

+$1.21 | +2.36%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$63.33

MKT CAP

$106.69B

52W Low

$42.52

VOL

$19.02M

P/E Ratio

17.7

AVG VOL

$15.75M

RSI

68.05

TREND

Uptrend

BMY Stock IQ

Login to see Bristol-Myers Squibb (BMY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BMY Target Price

Login to display

Strengths

BMY Rewards

Earnings are forecast to grow

BMY Rewards

Investors confidence is positive

BMY Rewards

Trading below its fair value

BMY Rewards

Upgraded on attractively valued

BMY Price Performance

$46.81 (+11.96%)

$45.02 (+16.41%)

$48.94 (+7.09%)

$57.68 (-9.14%)

1year

6month

3month

1month

BMY Risk Level

BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BMY Analysts Opinion

BMY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

BMY Analysts Opinion

BMY Analysts opinion is positive and also has improved from the past 3 months

BMY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

85%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

25%

NA

100%

BMY Street Sentiment

BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook

BMY Performance Sentiment

Sentiments overview associated with BMY events and the stock performance.

85%

0%

Positive

Negative

17 out of 20
events present

0 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$52.41

Resistance
Price

$45.79

Current Price Range

$52.41

Show methods +

Linked to BMY

IQ

Close Price

Change

JNJ

4.09

211.58

+0.75%

BMY Latest Analysis +

Bristol Myers Squibb Says FDA Grants Priority Review For Opdivo Combo. PDUFA Goal Date April 8 2026 . (RTTNews) - Bristol Myers Squibb Co. (BMY) announced Thursday that the United States Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with doxorubicin vinblastine and

Thu Dec 11, 2025

$51.20 | -0.03%

Activity

Jefferies Remains ish on Bristol-Myers Squibb Company (BMY).

Wed Dec 10, 2025

$51.21 | +1.11%

Potential

Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4 Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. [….]

Mon Dec 8, 2025

$51.67 | -0.92%

Activity

Potential

Scotiabank Maintains Bristol-Myers Squibb (BMY) Sector Perform Recommendation. Fintel reports that on December 4 2025 Scotiabank maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Sector Perform recommendation. Analyst Price Forecast Suggests 4.04% Upside

Fri Dec 5, 2025

$52.15 | +0.38%

Potential

Rating

FDA Approves Bristol Myers Squibbs Breyanzi As First CAR T Therapy For R/R Marginal Zone Lymphoma . (RTTNews) - Bristol Myers Squibb (BMY) announced that the United States Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel. liso-cel) a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory

Fri Dec 5, 2025

$52.15 | +0.38%

Activity

FDA Approves Bristol Myers Breyanzi For Relapsed/Refractory Marginal Zone Lymphoma . (RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzis approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who have received at least two prior lines of systemic therapy.

Fri Dec 5, 2025

$52.15 | +0.38%

Activity

Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Thu Dec 4, 2025

$51.95 | +1.94%

Activity

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It. Recently Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Wed Dec 3, 2025

$50.96 | +5.62%

Activity

Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation. Fintel reports that on December 2 2025 Goldman Sachs maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Neutral recommendation. Analyst Price Forecast Suggests 7.81% Upside

Wed Dec 3, 2025

$50.96 | +5.62%

Potential

Rating

Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates. Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data according to the firm offers tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis which bolsters trust in BMYS [….]

Wed Dec 3, 2025

$50.96 | +5.62%

Rating

FAQ About BMY Stock Insights

What is BMY current stock price?

What are BMY stock strengths?

What is BMY Risk Level?

What is BMY market cap and volume?

What is BMY current Stock IQ?

Should I buy BMY stock right now?

Is BMY a Strong Buy right now?

What does a 'Strong Buy' rating mean for BMY?

What does a 'Strong Sell' rating mean for BMY?

What factors influence BMY's Stock IQ?

Explore our BMY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BMY Stock Strategies
Effective Risk Management

FIND US ON

Receive our BMY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BMY

Bristol-Myers Squibb

Current Price

$52.41

+$1.21 | +2.36%

52W High

$63.33

MKT CAP

$106.69B

52W Low

$42.52

VOL

$19.02M

P/E Ratio

17.7

AVG VOL

$15.75M

RSI

68.05

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

BMY Rewards

Earnings are forecast to grow

BMY Rewards

Investors confidence is positive

BMY Rewards

Trading below its fair value

BMY Rewards

Upgraded on attractively valued

Linked to BMY

Symbol

IQ

Close

Change

JNJ

4.09

211.58

+0.75%

BMY Price Performance

$46.81 (+11.96%)

$45.02 (+16.41%)

$48.94 (+7.09%)

$57.68 (-9.14%)

1year

6month

3month

1month

BMY Analysts Opinion

BMY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

BMY Analysts Opinion

BMY Analysts opinion is positive and also has improved from the past 3 months

BMY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

85%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

25%

NA

100%

BMY Street Sentiment

BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook

BMY Risk Level

BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BMY Performance Sentiment

Sentiments overview associated with BMY events and the stock performance.

85%

0%

Positive

Negative

17 out of 20
events present

0 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$52.41

Resistance
Price

$45.79

Current Price Range

$52.41

Show methods +

BMY Stock IQ

Login to unlock Bristol-Myers Squibb (BMY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BMY Latest Analysis

Bristol Myers Squibb Says FDA Grants Priority Review For Opdivo Combo. PDUFA Goal Date April 8 2026 . (RTTNews) - Bristol Myers Squibb Co. (BMY) announced Thursday that the United States Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with doxorubicin vinblastine and

Thu Dec 11, 2025

$51.20 | -0.03%

Activity

Jefferies Remains ish on Bristol-Myers Squibb Company (BMY).

Wed Dec 10, 2025

$51.21 | +1.11%

Potential

Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4 Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. [….]

Mon Dec 8, 2025

$51.67 | -0.92%

Activity

Potential

Scotiabank Maintains Bristol-Myers Squibb (BMY) Sector Perform Recommendation. Fintel reports that on December 4 2025 Scotiabank maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Sector Perform recommendation. Analyst Price Forecast Suggests 4.04% Upside

Fri Dec 5, 2025

$52.15 | +0.38%

Potential

Rating

FDA Approves Bristol Myers Squibbs Breyanzi As First CAR T Therapy For R/R Marginal Zone Lymphoma . (RTTNews) - Bristol Myers Squibb (BMY) announced that the United States Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel. liso-cel) a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory

Fri Dec 5, 2025

$52.15 | +0.38%

Activity

FDA Approves Bristol Myers Breyanzi For Relapsed/Refractory Marginal Zone Lymphoma . (RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzis approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who have received at least two prior lines of systemic therapy.

Fri Dec 5, 2025

$52.15 | +0.38%

Activity

Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Thu Dec 4, 2025

$51.95 | +1.94%

Activity

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It. Recently Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Wed Dec 3, 2025

$50.96 | +5.62%

Activity

Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation. Fintel reports that on December 2 2025 Goldman Sachs maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Neutral recommendation. Analyst Price Forecast Suggests 7.81% Upside

Wed Dec 3, 2025

$50.96 | +5.62%

Potential

Rating

Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates. Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data according to the firm offers tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis which bolsters trust in BMYS [….]

Wed Dec 3, 2025

$50.96 | +5.62%

Rating

Discover BMY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BMY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BMY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BMY Stock trends

BMY Stock performance

BMY Stock analysis

BMY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BMY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BMY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

BMY Stock Analysis & IQ Rating | Bristol-Myers Squibb

BMY Stock IQ

BMY Target Price

BMY Risk Level

BMY Analysts Opinion

BMY Street Sentiment

BMY Performance Sentiment

Technical Price Levels

Explore our BMY Stock insights

Receive our BMY Daily Alerts

BMY Street Sentiment

BMY Risk Level

Technical Price Levels

Discover BMY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BMY. We're here to help you make informed investment decisions today.

Receive our BMY Daily Alerts

BMY Runner Alarm